EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice

Kaichi Kasai, Naoya Igarashi, Yuki Tada, Koudai Kani, Shun Takano, Tsutomu Yanagibashi, Fumitake Usui-Kawanishi, Shiho Fujisaka, Shiro Watanabe, Mayuko Ichimura-Shimizu iD, Kiyoshi Takatsu, Kazuyuki Tobe und 3 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24044050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kaichi Kasai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu 939-0398, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bile Acids and Salts, Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, The Toyama Pharmaceutical Valley Development Consortium, JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The potential roles of the gut microbiota in the pathogenesis of non-alcoholic fatty liver disease, including non-alcoholic steatohepatitis (NASH), have attracted increased interest. We have investigated the links between gut microbiota and NASH development in Tsumura-Suzuki non-obese mice fed a high-fat/cholesterol/cholate-based (iHFC) diet that exhibit advanced liver fibrosis using antibiotic treatments. The administration of vancomycin, which targets Gram-positive organisms, exacerbated the progression of liver damage, steatohepatitis, and fibrosis in iHFC-fed mice, but not in mice fed a normal diet. F4/80+-recruited macrophages were more abundant in the liver of vancomycin-treated iHFC-fed mice. The infiltration of CD11c+-recruited macrophages into the liver, forming hepatic crown-like structures, was enhanced by vancomycin treatment. The co-localization of this macrophage subset with collagen was greatly augmented in the liver of vancomycin-treated iHFC-fed mice. These changes were rarely seen with the administration of metronidazole, which targets anaerobic organisms, in iHFC-fed mice. Finally, the vancomycin treatment dramatically modulated the level and composition of bile acid in iHFC-fed mice. Thus, our data demonstrate that changes in inflammation and fibrosis in the liver by the iHFC diet can be modified by antibiotic-induced changes in gut microbiota and shed light on their roles in the pathogenesis of advanced liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsBile Acids and SaltsGastrointestinal MicrobiomeNon-alcoholic Fatty Liver DiseaseVancomycinAnimalsMiceDiet, High-FatDisease Models, AnimalLiverLiver CirrhosisMice, Inbred C57BL

Stichwörter der Autor:innen

antibioticbile acidcholic acidfibrosisgut microbiotainflammationmacrophagemetronidazolenon-alcoholic steatohepatitisvancomycin

Substanzen

Anti-Bacterial AgentsBile Acids and SaltsVancomycin

Autor:innen und Institutionen

  • Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 5180 Kurokawa, Imizu 939-0398, Japan.
  • Toyama Prefectural Institute for Pharmaceutical Research, 17-1 Nakataikouyama, Imizu 939-0363, Japan.
  • First Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
  • Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
  • Department of Pathology and Laboratory Medicine, Tokushima University Graduate School of Biomedical Sciences, 3-8-15 Kuramoto-cho, Tokushima 770-8503, Japan.

ORCID-Profile: Mayuko Ichimura-Shimizu, Koichi Tsuneyama, Yukihiro Furusawa, Yoshinori Nagai

Förderung

  • Japan Society for the Promotion of Science
  • The Toyama Pharmaceutical Valley Development Consortium
  • JSPS KAKENHI
  • Toyama Pharmaceutical Valley Development Consortium

Zitieren

APA

Kasai, K., Igarashi, N., Tada, Y., Kani, K., Takano, S., Yanagibashi, T., Usui-Kawanishi, F., Fujisaka, S., Watanabe, S., Ichimura-Shimizu, M., Takatsu, K., Tobe, K., Tsuneyama, K., Furusawa, Y., & Nagai, Y. (2023). Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24044050

Vancouver

Kasai K, Igarashi N, Tada Y, Kani K, Takano S, Yanagibashi T, et al. Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24044050

BibTeX
@article{Kasai2023,
  author = {Kasai, Kaichi and Igarashi, Naoya and Tada, Yuki and Kani, Koudai and Takano, Shun and Yanagibashi, Tsutomu and Usui-Kawanishi, Fumitake and Fujisaka, Shiho and Watanabe, Shiro and Ichimura-Shimizu, Mayuko and Takatsu, Kiyoshi and Tobe, Kazuyuki and Tsuneyama, Koichi and Furusawa, Yukihiro and Nagai, Yoshinori},
  title = {Impact of Vancomycin Treatment and Gut Microbiota on Bile Acid Metabolism and the Development of Non-Alcoholic Steatohepatitis in Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24044050}
}
Kostenlos starten →